Initiated First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors

We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.


Comments are closed.